

REMARKS

In response to the Official Action dated August 5, 2009 in which restriction has been required, Applicants hereby elect the invention identified as Group VI, i.e. claim 17 directed to a method for treating Alzheimer's disease, comprising administering the adeno-associated virus vector of claim 1 in a therapeutically effective amount to a subject.

All of previous claims 1-18 have been cancelled and have been replaced by new claims 19-29 directed to the elected invention.


In the new claims, new claim 19 is presented in independent form, combining claims 1 and 17.

The remaining claims depend on claim 19 and contain features from previous claims 3, 4, 6, 7, 9, 10, 12-14 and 16.

Favorable action on the merits is now requested.

Respectfully submitted,

Takeshi TABIRA et al.

By 
Matthew M. Jacob
Registration No. 25,154
Attorney for Applicants

MJ/kjf
Washington, D.C. 20005-1503
Telephone (202) 721-8200
Facsimile (202) 721-8250
September 1, 2009